The cytochrome P-450 arachidonic acid metabolite 20-HETE is central to the regulation of vascular tone, renal function, and blood pressure and is synthesized in the rat kidney in response to angiotensin II (ANG II) and endothelin-1 (ET-1). There are very few studies examining the cellular synthesis of 20-HETE in humans. We aimed to measure human neutrophil and platelet 20-HETE levels under basal conditions and after ANG II, ET-1, and calcium ionophore (CaI). 20-HETE was measured in human platelets and neutrophils after saline (control), CaI (2.5 g/ml), and ANG II or ET-1 (10 nmol/l-1 mol/l) incubations. The effect of cells, which were preincubated with the -hydroxylase inhibitor N-hydroxy-N=-(4-butyl-2-methylphenyl) (HET0016, 10 nM), ANG II types 1 or 2 (AT 1 or AT2) receptor inhibition with irbesartan (1 mol/l) or PD-123319 (1 mol/l), or endothelin receptor subtypes A or B (ET A or ETB) receptor inhibition with BQ-123 or BQ-778 (100 nmol/l), was studied. Neutrophil and platelet content and release of 20-HETE was significantly increased by CaI and blocked by the -hydroxylase inhibitor HET0016. ANG II and ET-1 significantly increased neutrophil and platelet content and release of 20-HETE. ANG II increased 20-HETE via the AT 2 receptor. ET-1 increased 20-HETE through the ET B receptor in platelets and both the ETA and ET B receptors in neutrophils. These studies show that human platelets and neutrophils synthesize 20-HETE in response to ANG II and ET-1. 20-HETE synthesis in both cell types was predominantly mediated via the AT 2 and ETB receptors. Stimulation via these receptor pathways has generally been thought to be cardioprotective and requires further studies in clinical situations associated with low-grade inflammation or where ANG II and ET-1 are elevated to clarify the role of 20-HETE.
ARACHIDONIC ACID can be metabolized by a number of different enzyme systems including cyclooxygenase and lipoxygenase to a range of bioactive metabolites. The cytochrome P-450 (CYP450) enzymatic pathway has received much less attention, but there is accumulating evidence that arachidonic acid metabolites formed by the microsomal CYP450 enzyme are central to the regulation of vascular tone, renal function, and blood pressure (31, 25) . Unlike the products of cyclooxygenase and lipoxygenase, arachidonic acid metabolites of the CYP450 pathway can be preformed and esterified in membrane phospholipids. Enzymes of the CYP4A, -4B, and -4F families catalyze -hydroxylation of fatty acids (31) . Several isoforms produce 20-hydroxyeicosatetraenoic acid (20-HETE) when incubated with arachidonic acid. In the vasculature, smooth muscle cells produce 20-HETE as a major product of CYP450 -hydroxylase metabolism (32) . 20-HETE causes vasoconstriction by the inhibition of potassium channels and may serve as an endogenous intracellular regulator of the potassium channel in arteriolar smooth muscle cells (20) . 20-HETE can act as a second messenger mediating the vascular actions of hormones such as endothelin-1 (ET-1) and angiotensin II (ANG II) (10, 11, 16) . In renal tissue a number of CYP isoforms are present, and although CYP4F2 is thought to be the isoform primarily responsible for 20-HETE synthesis in the kidney, CYP4F3 is also expressed (9) . Rat (33) and human neutrophils (1, 17) and human platelets (40) can also produce 20-HETE. In neutrophils the CYP4F3 isoform has a high affinity for leukotriene B 4 , metabolizing it to 20-hydroxyleukotriene B 4 as part of the deactivation and metabolic regulation of this potent chemotactic lipid (23) , but it is not known whether CYP4F3 is also responsible for 20-HETE synthesis.
Abnormalities in the production or actions of 20-HETE may be a potential mechanism for the pathogenesis of hypertension. There is already convincing evidence in the spontaneously hypertensive rat that either increased CYP expression or augmented 20-HETE synthesis is involved in vasoconstriction and impaired renal salt handling (25) . Blood pressure can be modified in the spontaneously hypertensive and Spraque-Dawley rats by gene delivery with CYP4A1 cDNA increasing blood pressure by 14 mmHg in Spraque-Dawley rats and antisense 4A1 cDNA decreasing blood pressure by 13.7 mmHg in the spontaneously hypertensive rats. This suggests that CYP hydroxylases contribute not only to the maintenance of normal blood pressure but also to the development of hypertension (39) . In mice, the genetic alteration of CYP4504A monooxygenase has also been shown to cause hypertension (18) . Little information is available on the involvement of 20-HETE in human hypertension, because inhibitors of CYP450 have not yet been approved for use in humans and the measurement of 20-HETE in cells and biological fluids is technically difficult. We recently showed that plasma 20-HETE and urinary 20-HETE excretion were raised in participants with features of the metabolic syndrome when compared, and age and sex matched, with healthy normotensive controls (37) .
The study of 20-HETE synthesis and release from different cells will increase our knowledge of the possible role of 20-HETE in the pathophysiology of various human disease states. In humans, platelets and neutrophils are both capable of 20-HETE synthesis and release and have receptors for ANG II (28, 36) and ET-1 (13, 36) . This raises the possibility of an integrated role for 20-HETE release from human platelets and neutrophils in response to the vasoconstrictors ANG II and ET-1. Such a system may have a homeostatic role in cardiovascular regulation, and its perturbation may be relevant to the pathophysiology of cardiovascular disease. The objectives of this study were, therefore, first, to quantify using GC-MS, neutrophil, and platelet 20-HETE release following stimulation with calcium ionophore and to confirm that the release of 20-HETE could be inhibited by the specific -hydroxylase inhibitor N-hydroxy-N=-(4-butyl-2-methylphenyl) (HET0016). Second, we examined the effects of the vasoactive peptides ANG II and ET-1 on the formation of 20-HETE in human neutrophils and platelets and characterized the receptors responsible for the release of 20-HETE stimulated by ANG II and ET-1.
METHODS

Recruitment of Volunteers
Healthy men aged between 20 -65 yr were recruited by newspaper advertisement from the general population. Volunteers had height, weight, and blood pressure measured. A fasted blood sample was taken for the measurement of total cholesterol, glucose, liver function tests, and creatinine. Volunteers were excluded from the study if they were smokers, consumed more than 70 g alcohol/wk or more than 20 g/day, had a history of chronic disease, or were taking antihypertensive agents, lipid-lowering drugs, aspirin, or nonsteroidal anti-inflammatory drugs. Volunteers were recruited over a 3-mo time period and gave blood samples on two separate occasions at least 2 wk apart for the experiments. Experiments examining the effect of inhibiting -hydroxylase and dose-response curves for ET-1 and ANG II were conducted on one day. Experiments examining the effect of ET-1 and ANG II receptor antagonists were conducted on the second day. All subjects provided written informed consent. The study was approved by the University of Western Australia Human Ethics Committee, and all procedures were in accordance with institutional guidelines. Fourteen men were studied. They visited the research unit having fasted for 12 h and provided a venous blood sample (50 ml) collected into EDTA (1 mg/ml), reduced glutathione (1 mg/ml), and butylated hydroxytoluene (BHT, 10 g/ml) for the measurement of neutrophil and platelet 20-HETE.
Neutrophil and Platelet 20-HETE and the Effect of Inhibiting -Hydroxylase
Neutrophil isolation. Neutrophils were prepared according to the method of Boyum (2) and resuspended in HEPES-buffered Hanks' solution containing 0.1% BSA to a concentration of 4.5 ϫ 10 6 cells/ml. Aliquots of 4.5 ϫ 10 6 cells were incubated with saline (control) or calcium ionophore A-23187 (2.5 g/ml in DMSO) for 15 min at 37°C. The neutrophil incubates were placed on ice and centrifuged at 4°C for 10 min at 2,000 g. BHT (10 g) was added to the neutrophil pellet and the supernatants, which were stored frozen at Ϫ80°C until assay.
Platelet isolation. Blood was centrifuged immediately at 150 g for 20 min. Platelet-rich plasma was separated, and the platelets were centrifuged and washed with 10 ml of 0.9% saline containing EDTA and BHT and then resuspended in HEPES-buffered Hanks' solution containing 0.1% BSA to a concentration of 1 ϫ 10 9 platelets/ml. Aliquots of 2 ϫ 10 8 cells were incubated with saline (control) or calcium ionophore (2.5 g/ml) for 15 min at 37°C. The platelet incubates were placed on ice and centrifuged at 4°C for 10 min at 2,000 g. BHT was added to the platelet pellet and supernatant, which were stored frozen at Ϫ80°C until assay.
The effect of inhibition of -hydroxylase on the release of 20-HETE in calcium ionophore-stimulated neutrophils or platelets was examined by preincubating platelets at 37°C for 15 min with 10 nM HET0016 before cell stimulation (26) .
Examination of the Effect of ANG II and ET-1 on Neutrophil and Platelet 20-HETE
Experiments incubating platelets or neutrophils with ANG II or ET-1 were conducted at concentrations of 0, 10, 100, and 1,000 nM in HEPES-buffered Hanks' solution without the addition of BSA for 30 min at 37°C. The characterization of the receptors involved with 20-HETE release by ANG II were examined incubating the platelets or neutrophils with either the ANG II type 1 (AT 1) receptor antagonist irbesartan at 1 mol/l or the ANG II type 2 (AT 2) receptor antagonist PD-123319 at 1 mol/l (28) for 15 min at 37°C before incubation with ANG II (1 mol/l) for 30 min at 37°C. The characterization of the receptors involved with 20-HETE release by ET-1 was examined by incubating the platelets or neutrophils with either the endothelin receptor subtype A (ET A) antagonist BQ-123 (100 nmol/l) or the endothelin receptor subtype B (ET B) antagonist BQ-788 (100 nmol/l) for 15 min at 37°C (36) before incubation with ET-1 (1 mol/l) for 30 min at 37°C (13) .
Effect of Inhibition of Nitric Oxide and Cyclooxygenase on Platelet and Neutrophil 20-HETE
To examine whether 20-HETE synthesis in neutrophils and platelets was modified by nitric oxide (NO) or prostaglandin release, experiments were conducted under basal and stimulated conditions. Calcium ionophore was chosen as the agent for stimulation since it most reproducibly increases 20-HETE in neutrophils and platelets. Neutrophils and platelets from three men were preincubated with N G -monomethyl-L-arginine (100 M) (24) or indomethacin (10 M) (11) for 30 min at 37°C before stimulation with the calcium ionophore A-23187 (2.5 g/ml) for 15 min.
Analysis of 20-HETE in Human Neutrophils and Platelets
The assay was a modification of the method previously described (37) and used 1 ng of d 6-20-HETE (Cayman Chemical) as an internal standard. The neutrophil and platelet pellets were subjected to alkaline hydrolysis (1 mol/l potassium hydroxide dissolved in methanol) at 40°C for 30 min under nitrogen. The neutrophil and platelet supernatants were assayed without base hydrolysis. The pH of samples was adjusted to 6.8 with 10% acetic acid, and the samples were applied to Bond elute Certify II columns that were prewashed with methanol and 0.1 M sodium acetate (pH 7.0) with 5% methanol. The column was then washed with methanol-water (50:50) and dried under vacuum (6 mmHg for 2 min) before elution of 20-HETE with hexane-ethyl acetate-acetic acid (75:25:1). The sample was dried and derivatized for GC-MS as previously described (30) .
Statistical Analysis
Paired t-tests were used to determine the differences between control (unstimulated) and stimulated 20-HETE levels obtained from the same experimental preparation. The data for the ANG II and ET-1 dose-response curves were log transformed to normalize the data before analysis. All statistical analysis was performed with the Statistical Package for the Social Sciences (SPSS, version 15.0), and a P value Ͻ 0.05 was considered statistically significant. Results are presented as means Ϯ SE.
RESULTS
The study participants were men, aged 53.7 Ϯ 2.2 yr, with a body mass index of 24.6 Ϯ 0.7 kg/m 2 and blood pressure of 116.5 Ϯ 3.4/69.2 Ϯ 2.6 mmHg. They had normal liver and renal function. Their cholesterol and fasting glucose were 5.0 Ϯ 0.2 and 4.2 Ϯ 0.1 mmol/l, respectively.
Neutrophil and Platelet 20-HETE and the Effect of Inhibiting -Hydroxylase
The incubation of neutrophils or platelets with saline (control) showed that measurable amounts of 20-HETE were released into the supernatant, 38.4 Ϯ 5.6 pg/10 6 neutrophils, and 4.5 Ϯ 1.9 pg/10 8 platelets, respectively. Calcium ionophore significantly increased the release of 20-HETE into the supernatant (104.9 Ϯ 11.9 pg/10 6 neutrophils, P Ͻ 0.001; and 11.8 Ϯ 3.7 pg/10 8 platelets, P ϭ 0.021). The addition of the -hydroxylase inhibitor HET0016 before calcium ionophore stimulation inhibited 20-HETE synthesis, resulting in a markedly reduced 20-HETE release from both neutrophils (47.3 Ϯ 6.1 pg/10 6 neutrophils, P Ͻ 0.001; Fig. 1A ) and platelets (7.1 Ϯ 3.0 pg/10 8 platelets, P ϭ 0.001; Fig. 1B ). The esterified 20-HETE in the neutrophil and platelet pellets was measured after alkaline hydrolysis and was 18.7 Ϯ 2.5 pg/10 6 neutrophils and 15.8 Ϯ 2.4 pg/10 8 platelets, respectively, after incubation with saline (control). Stimulation with calcium ionophore significantly increased the level of esterified 20-HETE in both neutrophils and platelets (P Յ 0.001; Fig. 1 ). The addition of the -hydroxylase inhibitor HET0016 before incubation with calcium ionophore significantly inhibited the production of 20-HETE in both neutrophils and platelets (P Ͻ 0.001; Fig. 1, black bars) .
Examination of the Effect of ANG II and ET-1 on Neutrophil and Platelet 20-HETE
The release of 20-HETE from human neutrophils and platelets stimulated with ANG II is shown in Fig. 2 . When compared with that in control neutrophil incubation, only stimulation with ANG II at a dose of 1 M significantly increased the release of 20-HETE from neutrophils ( Fig. 2A) . In platelets, all doses of ANG II led to significant increases in the release of 20-HETE (Fig. 2B) . In contrast, the 20-HETE content of the neutrophil and platelet pellets was significantly increased by all doses of ANG II.
The release of 20-HETE from human neutrophils and platelets stimulated with ET-1 is shown in Fig. 3 . When compared with that in control neutrophil incubation, only stimulation with ET-1 at 1 M significantly increased the release of (Fig. 3A) . In platelets, all doses of ET-1 led to significant increases in the release of 20-HETE (Fig. 3B) . In contrast, the 20-HETE content of neutrophil and platelet pellets were significantly increased by all doses of ET-1.
20-HETE from neutrophils
Preincubation of cells with the AT 1 receptor blocker irbesarten did not inhibit ANG II-stimulated neutrophil or platelet content or release of 20-HETE (Fig. 4, A and B) . In contrast, incubation with the AT 2 receptor blocker PD-123319 significantly inhibited both neutrophil and platelet content and release of 20-HETE (Fig. 4, A and B) .
ET-1-stimulated neutrophil 20-HETE content but not release was inhibited by the ET A receptor blocker BQ-123 and the ET B receptor blocker BQ-778 (Fig. 5, A and B) . In contrast, ET-1-stimulated platelet content and release of 20-HETE were significantly inhibited by the ET B receptor blocker BQ-778 but not BQ-123 (Fig. 5, A and B) .
Effect of inhibition of NO and cyclooxygenase on platelet and neutrophil 20-HETE. There was no significant effect of the inhibition of either NO or prostaglandin synthesis on 20-HETE synthesis in either neurophils (Fig. 6A) or platelets (Fig. 6B) .
DISCUSSION
In this study we examined esterified cellular 20-HETE and free 20-HETE released into the supernatant upon incubation under basal conditions or after stimulation. We showed that 20-HETE is present in and released from neutrophils and platelets under basal conditions. The cellular content and release were substantially increased in response to calcium ionophore, ANG II, and ET-1. We showed that the stimulation of neutrophils and platelets with calcium ionophore resulted in a significant increase in the cellular 20-HETE content and cellular 20-HETE release into the supernatant. There were notable differences in the quantity and distribution of 20-HETE in the two cell types. The 20-HETE content was ϳ100-fold higher in the neutrophil compared with the platelet. In addition, the incubation of neutrophils alone or with calcium ionophore stimulation led to the majority of the 20-HETE being released into the supernatant, whereas in the platelet the majority of the 20-HETE remained within the cells. These observations suggest that in the neutrophil there is a synthesis of 20-HETE via -hydroxylase and a rapid release of most of the 20-HETE into the supernatant, probably by the activation of phospholipase A 2 . A previous study by Hill and Murphy (17) showed that 20-HETE was significantly elevated when neutrophils were incubated with calcium ionophore (17) , but this is the first report to describe the distribution of 20-HETE esterified in the neutrophil and that released as free 20-HETE. In contrast, in the platelet the increase in 20-HETE following stimulation with calcium ionophore is distributed more equally between the platelet and the supernatant, suggesting that the release of 20-HETE from the platelet under basal and stimulated conditions is less efficient than in the neutrophil. Unlike prostaglandins that are synthesized from free arachidonic acid and then metabolized and excreted, the CYP450 metabolites 20-HETE and epoxyeicosatrienoic acids can be released and reesterified within the cellular membranes (31) . Therefore, an alternative explanation for elevated 20-HETE in platelet membranes could be a more efficient reesterification of 20-HETE into the membranes during incubation. Our results concur with those of Zhu et al. (40) who could only detect 20-HETE in platelet pellets after hydrolysis with phospholipase A 2 . The incubation of both cell types with the selective -hydroxylase inhibitor HET0016 significantly inhibited the calcium ionophore-induced increase in neutrophil and platelet content and release of 20-HETE (26), suggesting that -hydroxylase is necessary for 20-HETE synthesis.
We found that ANG II increased both neutrophil and platelet content and release of 20-HETE. This also suggests an increase in synthesis of 20-HETE by -hydroxylase rather than an activation of phospholipase A 2 by ANG II, followed by the release of preformed esterified 20-HETE. Our result is consistent with studies examining renal cortical cells in the Ren-2 transgenic rat, an ANG II-dependent model of hypertension, where elevated renal -hydroxylase activity and 20-HETE levels have been shown (8) . Our study examined the effect of the AT 1 receptor antagonist losartan and the AT 2 receptor antagonist PD-123319 on the ANG II-dependent increase in 20-HETE and found that it was abolished by PD-123319. Similarly, the ANG II increase in 20-HETE in platelets was also mediated via the AT 2 receptor. Our experiments, preincubating the cells with AT 1 receptor blocker losartan and the AT 2 receptor blocker PD-123319, clearly demonstrate that the increase in 20-HETE in response to ANG II was via the AT 2 receptor in both neutrophils and platelets. This result is consistent with the study of Croft et al. (11) who showed that 20-HETE in rat renal arterioles in response to ANG II was via the AT 2 receptor and other studies that have shown that ANG II markedly increases the formation (7) and promotes the release of 20-HETE from the isolated rabbit kidney (6) . Neutrophils have been previously shown to have both AT 1 and AT 2 receptors on their surface (28, 29) . In the platelet most studies have focused on the AT 1 receptor that, when inhibited, leads to reduced thromboxane A 2 -mediated aggregation (27) and to NO release in the platelet (22) . Studies have suggested that the intracellular signaling of AT 1 occurs via a G protein coupled to phospholipase, followed by calcium signaling from the intracellular pool (35) , whereas the signal transduction pathways for the AT 2 receptor are not well understood. They do not appear to involve a G protein (5) and may differ from AT 1 signaling pathways (21) . ANG II has also been shown to induce oxidative stress in neutrophils and platelets, but this is mediated via the AT 1 receptor (12, 15) and therefore independent of the ANG II effects on 20-HETE. Given the important role of 20-HETE as a potent vasoconstrictor (31) and the protective role of AT 2 receptor in blood pressure regulation (19, 33, 34) , further studies are required to define the role of 20-HETE release from neutrophils and platelets in situations where ANG II levels are elevated.
This study has also shown for the first time that ET-1 can significantly increase both neutrophil and platelet content and release of 20-HETE. The results suggest that ET-1 is stimulating 20-HETE synthesis via -hydroxylase rather than activating phospholipase A 2 to release preformed 20-HETE. We examined the receptor responsible for the ET-1 increase in 20-HETE, using the ET A receptor blocker BQ-123 and the ET B receptor blocker BQ-788. We found that the responses in platelets were mediated via the ET B receptor. Interestingly, the level of esterified 20-HETE in ET-1-stimulated neutrophils was reduced by the ET B receptor antagonist BQ-788 and to a lesser extent the ET A receptor antagonist BQ-123, but neutrophil 20-HETE release was unaffected by these antagonists. These findings are consistent with an interaction of both ET A and ET B receptor subtypes in human neutrophils in ET-1-stimulated 20-HETE release. Pharmacological and receptor binding studies have indicated that human neutrophils express mainly ET A receptors (41) . The role of ET B receptor in ET-1 clearance is well recognized (4, 14) ; however, it has been suggested that ET A and ET B may form homo-and heterodimers upon agonist stimulation (3). This phenomenon may in part explain the dual inhibitory effect of both ET A and ET B antagonists on 20-HETE in the neutrophil. Further studies are needed to elucidate the mechanism underlying the release of 20-HETE from human blood cells and to explain the different observations in human platelets and neutrophils stimulated with ET-1.
The doses of ANG II and ET-1 used in our studies were relatively high, and although local concentrations at sites of inflammation may be elevated, further studies will be required to examine the effect of this agent at more physiological concentrations.
We examined the role of NO and cyclooxygenase on basal and calcium ionophore-stimulated 20-HETE synthesis in human platelets and neutrophils using the inhibitors N G -monomethyl-L-arginine and indomethacin. We did not find that the inhibition of NO or cyclooxygenase modified basal or stimulated 20-HETE release.
In summary, we have shown that platelets and neutrophils can synthesize 20-HETE in response to the vasoconstrictor agents ANG II and ET-1. The AT 2 receptor is responsible for the ANG II-induced increase in 20-HETE in both neutrophils and platelets. This finding reflects observations that receptor activation by ANG II can induce 20-HETE synthesis in renal microvessels and suggests that platelets and neutrophils may be useful as surrogate cells for studying 20-HETE responses in humans. ET B receptors are responsible for an ET-1-induced increase in platelet 20-HETE content and release. By contrast, in neutrophils both ET A and ET B are responsible for mediating the increase in 20-HETE content. In general, 20-HETE synthesis in both cell types is predominantly via the AT 2 and ET B receptors, receptor pathways that are generally thought to be cardioprotective. Therefore, their future study in clinical situations associated with low-grade inflammation or where ANG II and ET-1 are elevated will be required to further clarify our understanding of the role of 20-HETE in cardiovascular and blood pressure regulation.
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